Cited by

• Clinical pharmacokinetics and pharmacodynamics of clopidogrel.

  Jiang XL, Samant S, Lesko LJ, Schmidt S. Jiang XL, et al. Clin Pharmacokinet. 2015 Feb;54(2):147-66. doi: 10.1007/s40262-014-0230-6. Clin Pharmacokinet. 2015. PMID: 25559342 Free PMC article. Review.
• Prevalence of CYP2C19 and ITGB3 polymorphisms among Bangladeshi patients who underwent percutaneous coronary intervention.

  Islam MR, Nova TT, Momenuzzaman N, Rabbi SNI, Jahan I, Binder T, Islam MS, Hasnat A, Nahar Z. Islam MR, et al. SAGE Open Med. 2021 Aug 26;9:20503121211042209. doi: 10.1177/20503121211042209. eCollection 2021. SAGE Open Med. 2021. PMID: 34471538 Free PMC article.
• Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness.

  Scott SA, Martis S, Peter I, Kasai Y, Kornreich R, Desnick RJ. Scott SA, et al. Pharmacogenomics J. 2012 Aug;12(4):297-305. doi: 10.1038/tpj.2011.5. Epub 2011 Mar 1. Pharmacogenomics J. 2012. PMID: 21358751 Free PMC article.
• Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics.

  Ned Mmsc Phd RM. Ned Mmsc Phd RM. PLoS Curr. 2010 Sep 20;2:RRN1180. doi: 10.1371/currents.RRN1180. PLoS Curr. 2010. PMID: 20877456 Free PMC article.
• Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

  Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. Mega JL, et al. JAMA. 2010 Oct 27;304(16):1821-30. doi: 10.1001/jama.2010.1543. JAMA. 2010. PMID: 20978260 Free PMC article.